I(nsp1)ecting SARS-CoV-2-ribosome interactions. by Simeoni, M. et al.
 1 
I(nsp1)ecting SARS-CoV-2 - ribosome interactions 1	
Matthieu Simeoni1,§, Théo Cavinato1,§, Daniel Rodriguez1,§, David Gatfield1* 2	
1) Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland 3	
§ These authors contributed equally 4	
* corresponding author: david.gatfield@unil.ch 5	
Abstract 6	
While SARS-CoV-2 is causing modern human history’s most serious health crisis 7	
and upending our way of life, clinical and basic research on the virus is advancing 8	
rapidly, leading to fascinating discoveries. Two studies have revealed how the viral 9	
virulence factor, nonstructural protein 1 (Nsp1), binds human ribosomes to inhibit 10	
host cell translation. Here, we examine the main conclusions on the molecular 11	
activity of Nsp1 and its role in suppressing innate immune responses. We discuss 12	
different scenarios potentially explaining how the viral RNA can bypass its own 13	
translation blockage and speculate on the suitability of Nsp1 as a therapeutic 14	
target.	  15	
 2 
Introduction 16	
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes the disease COVID-17	
19 that has led to one of the most serious health crises in modern history1. First identified in 18	
Wuhan, China, the virus subsequently spread around the world and was declared a pandemic 19	
in March 20202. At the time of writing (December 2020), SARS-CoV-2 has worldwide killed more 20	
than 1.5 million people and infected almost 70 million according to the World Health 21	
Organization3. Shortly after China reported its first confirmed cases of infection, the causative 22	
agent of COVID-19 was identified as a member of the Sarbecovirus subgenus of the genus 23	
Betacoronavirus4,5, which also includes two already known causative agents of epidemics: 24	
Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV, or SARS-CoV-1) and Middle 25	
East Respiratory Syndrome Coronavirus (MERS-CoV)6. Although SARS-CoV-2 shares part of 26	
its genome with SARS-CoV-1 and MERS-CoV (approximately 80% and 50%, respectively)5,7, it 27	
has a higher rate of spread and its symptoms develop after a longer incubation period, making 28	
it a major threat to global health. 29	
SARS-CoV-2 is an enveloped positive-stranded RNA virus5. Its 30 kb genome comprises a 30	
5’-cap and 5’ untranslated region (5’ UTR), followed by 10 individual protein-coding open 31	
reading frames (ORFs), and terminates with a 3’ UTR that is polyadenylated (Figure 1a). The 3’ 32	
portion of the genome encodes several typical viral structural proteins, such as spike (S), 33	
envelope (E), membrane (M) and nucleocapsid (N) proteins, whereas in the genome’s 5’ portion 34	
two large overlapping ORFs of gene 1 encode the ORF1a/b polyprotein, from which several 35	
nonstructural proteins (Nsps) arise through proteolytic cleavage. Among the 16 nonstructural 36	
proteins (Nsp1-16), Nsp1 is encoded at the very 5’ end of ORF1a (Figure 1a) and is the first 37	
coronaviral protein produced in infected cells8. Previous work on SARS-CoV-1 reported several 38	
activities for Nsp1: it can suppress host translation by interacting with the ribosomal 40S subunit 39	
and inhibiting 80S formation9,10, and it can induce mRNA cleavage and decay11,12, leading to an 40	
inhibition of cell-intrinsic innate immune responses13,14. Of note, the mechanisms by which Nsp1 41	
proteins operate may vary across beta-CoVs15: for instance, it has been reported that MERS-42	
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CoV Nsp1 does not stably bind the ribosomal 40S subunit and - in line with its intracellular 43	
distribution that is both cytoplasmic and nuclear - that it possesses an RNA degradation activity 44	
that differs from that of the exclusively cytoplasmic SARS-CoV-1 Nsp116. Whether and how 45	
SARS-CoV-2 Nsp1 can inhibit translation has remained poorly understood until recently, with 46	
two studies by Schubert et al.17 and Thoms et al.18 now providing insights into how Nsp1 binds 47	
to the 40S subunit of the ribosome and blocks the mRNA entry channel. Using cryo-electron 48	
microscopy, the two studies highlight areas of interaction between Nsp1 and the ribosome and 49	
show that the 5’ UTR of the viral transcript enhances its translation. Notably, the inhibition by 50	
Nsp1 has direct effects on the host immune response, in line with previous work9. 51	
In this review, we describe how the recent structural work17,18 has improved our 52	
understanding of SARS-CoV-2 Nsp1-mediated translation inhibition. We also discuss which 53	
mechanisms may be responsible to sustain viral protein translation even under conditions when 54	
Nsp1 inhibits the ribosome. Finally, because Nsp1 is essential for efficient SARS-CoV-2 55	
replication, understanding the molecular mechanisms that underlie its activity may be relevant 56	
for the development of effective therapeutic treatments and vaccines. We highlight how Nsp1 57	
inhibition would likely impact host immune responses and inhibit viral replication. 58	
Nsp1 blocks the mRNA entry channel 59	
Nsp1 from SARS-CoV-2 has 84% amino acid sequence identity with its SARS-CoV-1 ortholog. 60	
Such high conservation suggests common biological properties and functions. For SARS-CoV-61	
1, Nsp1 can lead to an almost complete halt in host translation (and, thus, antiviral defence 62	
mechanisms that depend on de novo gene expression), and the protein interacts with the human 63	
40S ribosomal subunit with the help of a Lys164-His165 (K164, H165) dipeptide motif14. These 64	
residues are conserved in SARS-CoV-2 (Figure 1a), arguing for functional orthology. How, 65	
precisely, does SARS-CoV-2 Nsp1 bind to the ribosome, and what is the mechanism underlying 66	
translational inhibition? To address these questions, Schubert et al.17 and Thoms et al.18 67	
followed similar strategies: first, they used cryo-electron microscopy to determine the structure 68	
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of Nsp1 bound to host ribosomal complexes. Second, they designed cellular and biochemical 69	
experiments to investigate the main hypotheses on how Nsp1 affects translation. While the 70	
central conclusions from both studies are overlapping and complementary, the actual Nsp1-71	
ribosome complexes that they report on are at first sight surprisingly diverse. The main reason 72	
likely lies in different methodological approaches. Briefly, Schubert et al. incubated Nsp1 that 73	
was recombinantly produced in bacteria, with human	 embryonic kidney (HEK) 293E cell 74	
extracts, and purified the resulting Nsp1-ribosomal complexes on sucrose gradients17. The 75	
structures of two main complexes were solved at atomic resolution, the first corresponding to 76	
Nsp1 with a 40S ribosomal subunit and the second together with an 80S ribosome. The 40S 77	
subunit-containing structure showed all features of a 43S pre-initiation complex (PIC) (i.e., it 78	
contained the eIF3-core, eIF1 and initiator tRNA-loaded eIF2 proteins) with Nsp1 occupying the 79	
mRNA entrance channel. The 80S structure corresponded to a translationally inactive ribosome 80	
with an E-site (exit site) tRNA, but lacking mRNA; again, the mRNA entrance channel was 81	
blocked by Nsp1. The main strategy pursued by Thoms et al.18 was based on expressing tagged 82	
Nsp1 in HEK293T cells, followed by Nsp1 affinity purification to isolate native complexes from 83	
the cell lysates. The structures of nine distinct Nsp1-containing 40S and 80S complexes were 84	
solved. Among the five different 40S complexes, two were in a PIC state, similar to that reported 85	
by Schubert et al.17, whereas three others did not correspond to initiation intermediates. Briefly, 86	
two of them contained a ribosomal biogenesis factor, TSR1, indicating a “pre-40S state”, while 87	
the third was a simple Nsp1-40S association. Of the four distinct Nsp1-80S complexes, two 88	
contained an additional protein (CCDC124) that occupied the A-site (aminoacyl site), possibly 89	
indicating a ribosome recovery/recycling state. In the two other 80S complexes, a protein that 90	
has previously been implicated in pre-rRNA processing and antiviral responses, termed LYAR, 91	
occupied the A-site. It is unclear whether these rather exotic complexes and conformations had 92	
been induced by the presence of Nsp1, or whether Nsp1 had trapped natural intermediates that 93	
thus became purifiable. Moreover, it is unknown what relevance these complexes have in 94	
SARS-CoV-2 infected cells. 95	
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In all the above complexes, Nsp1 obstructed the mRNA entry channel, consistent with 96	
translational inactivity. How, precisely, is mRNA entry blocked by Nsp1? The two studies 97	
uncovered the molecular basis of a tight interaction that relies on the C-terminal region of Nsp1, 98	
which folds into two helices that insert into the mRNA entrance channel (Figure 1b). The first C-99	
terminal helix (residues 153-160) makes hydrophobic interactions with 40S ribosomal proteins 100	
uS3 and uS5, and the second C-terminal helix (residues 166-178) interacts with ribosomal 101	
protein eS30 and helix h18 of the 18S rRNA. In between the two helices, the conserved KH 102	
dipeptide (K164 and H165) forms critical interactions with h18 that are based on H165 stacking 103	
between two uridines of 18S rRNA (U607 and U630), and electrostatic interactions between 104	
K164 and the phosphate backbone of rRNA bases G625 and U630. 105	
In summary, the cryo-EM structures give detailed insights into how Nsp1 uses its C-terminus 106	
to cling onto the mRNA entry channel, thus precluding transcript recruitment. Of note, this 107	
mechanism may be particular to SARS-CoV-2 and its closest relatives, given that the Nsp1 C-108	
terminus is shorter and less conserved in more distantly related viruses, including MERS-CoV 109	
(Figure 1a). Two obvious questions arise from the structural data. First: what is the function of 110	
the protein’s N-terminal domain? The cryo-EM data of both studies indicate that the N-terminus 111	
adopts a globular shape, flexibly connected to the C-terminus - yet its precise structure remains 112	
undefined. When the Nsp1 N-terminus is replaced by an unrelated protein sequence, this fusion 113	
still inhibits translation in in vitro assays, indicating that this part of Nsp1 is not required for 114	
translation inhibition per se17. The N-terminus may thus act in other processes, possibly in 115	
analogy to Nsp1 from SARS-CoV-1 that can regulate mRNA stability and suppress host immune 116	
functions13,14. The second intriguing question is: how does the virus ensure translation of its own 117	
RNA? We will discuss various hypotheses in the next section. 118	
Viral gene expression needs to bypass global translation inhibition 119	
If Nsp1 binds with high affinity to the ribosome to inhibit translation in a potentially global fashion, 120	
an obvious paradox arises: how can the virus produce the proteins necessary for its own 121	
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replication? The above studies17,18, together with other recent publications, have given rise to 122	
several hypotheses on how viral protein translation may be achieved (Figure 2). 123	
The viral 5’ UTR overrides the translation block (Figure 2b). Schubert et al. demonstrate that 124	
the highly structured viral 5’ UTR is likely critical to overcome the Nsp1-mediated translation 125	
block17. In in vitro translation assays, fivefold more protein was produced from a luciferase 126	
reporter RNA carrying the viral 5’ UTR as compared to an identical amount of reporter RNA 127	
without the viral 5’ UTR. Nevertheless, Nsp1 inhibited the translation of both reporters in a 128	
similar, dose-dependent fashion. This finding suggests that at Nsp1 expression levels that do 129	
not shut down translation completely, the viral transcript will have a kinetic advantage over 130	
cellular transcripts to be recruited for translation. Two recent studies19,20 go further in 131	
characterizing the mechanisms involved in lifting the translation block so that viral protein 132	
biogenesis can proceed. Analogous to previous observations that had been made using SARS-133	
CoV-1 Nsp121, Shi et al., in their non-peer-reviewed publication available as a preprint, 134	
demonstrate that the N-terminal domain of SARS-CoV-2 Nsp1 interacts with the viral 5’ UTR19. 135	
Moreover, when the physical distance between the Nsp1 C-terminus (that anchors the protein 136	
on the 40S subunit, as described above) and the N-terminus (that interacts with the 5’ UTR19) 137	
is increased through a linker, the viral 5’ UTR-containing RNA loses the ability to escape 138	
translational inhibition. While the precise molecular details of these observations remain to be 139	
elucidated, a short stem loop at the very 5’ end of the viral UTR, termed SL1, appears to play a 140	
critical role. SL1 is necessary but not sufficient to bypass the inhibition. Shi et al.19 speculate 141	
that the study by Schubert et al.17 had not detected this mechanism because the reporter 142	
constructs did not contain the short SL1 sequence - an attractive hypothesis that, however, will 143	
require dedicated further experiments for validation. In analogy to the SARS-CoV-1 findings, 144	
one may nevertheless speculate that the SL1-Nsp1 interaction would lead to the recruitment of 145	
host factors which enhance translation, and/or induce conformational changes within Nsp1 146	
which induce its detachment from 40S. 147	
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Host mRNA degradation through Nsp1. In addition to the role in blocking translation, it is quite 148	
possible that SARS-CoV-2 Nsp1 also induces the degradation of host mRNA molecules. In so 149	
doing, the ratio of viral to host mRNA would be increased, and the production of viral proteins 150	
would be favoured. Of note, this hypothesis lacks direct evidence for the moment and is an 151	
extrapolation from findings in SARS-CoV-1 and MERS-CoV, where the corresponding Nsp1 152	
orthologs possess such (endo)nucleolytic activity directed towards host mRNAs9,12,22. Cleaved 153	
host mRNAs lack their 5’ cap and are not only translationally inactive, but susceptible to full 154	
decay through the cellular degradation machinery. Notably, Lokugamage et al.10 were able to 155	
identify a SARS-CoV-1 Nsp1 mutant protein (R124A, K125A) lacking mRNA cleavage activity. 156	
These amino acids are conserved in SARS-CoV-2 and the analogous mutant Nsp1 could 157	
represent an ideal starting point to explore whether a similar mRNA decay activity is associated 158	
with Nsp1 in this virus as well. For the moment, however, direct biochemical evidence of an 159	
intrinsic mRNA cleavage activity of SARS-CoV-2 Nsp1 is still lacking.  160	
Nsp1 autoregulation. Even though the virus shifts translational capacity from host mRNA to its 161	
own RNA, a complete switch is (teleologically speaking) likely also not in the viral interest. In 162	
particular, it would be plausible that the virus has optimized the system in a way that host 163	
proteins necessary for viral replication can still be produced. First, one should consider that 164	
every mammalian cell harbours several million ribosomes23; it is unclear whether and with what 165	
kinetics during viral infection Nsp1 abundance can reach similar concentrations at all. Moreover, 166	
if viral mRNAs accumulate to very high levels - as suggested by the non-peer-reviewed study 167	
available as a preprint by Puray-Chavez et al.24, who found that in Vero E6 cells more than 80% 168	
of RNA-seq reads were of viral origin 48h post-infection - even relatively inefficient translation 169	
may be sufficient for viral reproduction. Finally, Schubert et al.17 provide some evidence for Nsp1 170	
autoregulation, which could contribute to establishing the optimal balance between a host 171	
translation inhibitory and permissive situation. Briefly, by transfecting equal amounts of Nsp1-172	
encoding plasmid DNA into Hela cells, Schubert et al. observed a lower level of Nsp1 protein in 173	
cells transfected with wild-type Nsp1 than in cells transfected with Nsp1 that was mutated at its 174	
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KH motif, potentially due to negative feedback of functional Nsp1 on its own translation. Further 175	
evidence will be required to understand the molecular basis and physiological relevance of the 176	
proposed negative feedback mechanism. 177	
Translational inhibition engenders a kinetic advantage over the host immune response 178	
A critical host response to viral infection is the activation of cell-intrinsic innate immune 179	
responses. RIG-I-like receptors (RLRs) are among the main actors in the detection of viral RNA 180	
and coronavirus infection25. Once activated, the RLR signalling cascade induces the expression 181	
of type I interferons (IFNs), which trigger innate antiviral immune responses aimed at 182	
suppressing viral replication and spreading at an early stage. These mechanisms are well 183	
established to occur in SARS-CoV-1 infection14,26, yet SARS-CoV-2 may elicit them only poorly. 184	
Thoms et al.18 investigated a potential involvement of Nsp1 in their suppression. They expressed 185	
a wild-type or mutant version (K164A, H165A; defective in 40S interaction) of Nsp1 in HEK293T 186	
cells and then activated the cellular RLR pathway. Wild-type Nsp1, but not the mutant protein, 187	
virtually shut down the translation of transcripts induced by IFN-β. Importantly, despite the strong 188	
reduction in translated proteins, the corresponding mRNA levels were not affected. It would 189	
therefore seem that the effect of Nsp1 is restricted to translational inhibition with little, if any, 190	
direct effect on immune response gene transcription and mRNA stability. It will be interesting to 191	
evaluate whether this effect on innate immune response gene expression is a reflection of the 192	
general block of translation, or whether there is additional specificity for this class of transcripts. 193	
Finally, it will be important to evaluate to what extent we can extrapolate from such experiments 194	
in one specific, transformed cell line (HEK293T) that expresses Nsp1 in the absence of other 195	
coronaviral factors (but contains adenoviral E1a and E1b proteins), to a real SARS-CoV-2 196	
infection. After all, the latter is associated with a robust, though delayed antiviral response, 197	
mediated by two RIG-I-like receptors, MDA5 and LGP227,28. Nsp1 may be responsible for the 198	
observed delay, either through the translational inhibition it exerts, or through other, additional 199	
mechanisms for which evidence is mounting. Several viral proteins (including Nsp1, when 200	
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overexpressed) thus inhibit IFN induction by suppressing the activation of STAT1/2 transcription 201	
factors, which are critical effectors of the cascade13,29-32. Taken together, it is plausible that the 202	
multilevel interaction with the interferon response system will give SARS-CoV-2 a kinetic 203	
advantage over an immune response that is normally rapidly mounted. This characteristic 204	
appears to be one of the reasons why COVID-19 differs from SARS-CoV-1 and MERS 205	
infections22, and Nsp1 seems to play a specific, critical role. 206	
Nsp1 - Achilles’ heel of SARS-CoV-2? 207	
Given the important functions of Nsp1 that have been revealed, could this protein actually 208	
constitute a vulnerability of the virus relevant for the development of a future drug or vaccine? 209	
Conceptually, a drug designed to target Nsp1 would need to prevent its binding to the ribosome 210	
without interfering with ribosomal function, thus allowing the cellular defence systems to mount 211	
a response. As recently shown by Xia et al.29, the development of small molecule drugs targeting 212	
ribosomal RNAs could be a possible strategy to disrupt the interaction between Nsp1 and 18S 213	
rRNA. Another promising strategy could lie in targeting the 5’ viral leader; indeed, if the first loop 214	
of the stem (SL1) is sufficient to prevent the suppression of translation during the expression of 215	
Nsp1, as suggested by Banerjee et al.20, it might be possible to design small molecules or 216	
antisense oligonucleotides that bind specifically to the relevant part of the RNA. 217	
From a public health perspective, the most important approach to combat the devastating 218	
infectious impact of SARS-CoV-2 lies in the development of vaccines. We are seeing significant 219	
progress at the moment in this regard, with several efficient vaccines on the market. 220	
Nevertheless, given that vaccination will need to stop the replication of the virus globally, and 221	
that vaccine escaper variants will likely emerge over time, it will remain of importance to develop 222	
additional vaccines and treatments to cure infected individuals as well. Vaccines are typically 223	
designed using proteins that are on the surface of the viral particles. Nevertheless, if Nsp1 is as 224	
essential as suggested for an infection, and likely does not easily tolerate mutations that would 225	
help evade immune system recognition, the design of a vaccine based on this protein could be 226	
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an interesting complementary strategy. Also, an attenuated virus, e.g. lacking the essential KH 227	
motif that is critical for ribosome binding and translation inhibition, could potentially be 228	
envisioned as it would enable an effective host immune response in addition to generating the 229	
immune memory essential to combat new SARS-CoV-2 infections. 230	
Conclusion 231	
Historically, many important discoveries in molecular biology have been made through the study 232	
of viruses. The fascinating structural work on Nsp1-ribosome complexes is enlightening for our 233	
fundamental understanding of cellular processes and their high-jacking during viral attack. 234	
Although SARS-CoV-2 is becoming better understood day by day, much research is still 235	
needed, in particular to understand how the various effects discussed above in isolation are 236	
integrated together (e.g. those on translation, with those presumably acting on host mRNA 237	
abundance), thus leading to the reprogramming of the host cell gene expression landscape. 238	
Surprising (and sometimes contradictory) findings show us that we are far from fully 239	
understanding the complexity of the system. For instance, a recent study by Finkel et al. 33 has 240	
shown that viral mRNAs are not translated more efficiently than host mRNAs, in apparent 241	
contradiction to some of the data discussed above. Instead, the authors propose that it is simply 242	
the high levels of viral transcripts that explain how viral translation dominates host translation. 243	
Also, a detailed time-course study of the transcriptome of SARS-CoV-2-infected cells would be 244	
revealing to identify which host genes are directly impacted by the virus. A first step in this 245	
direction is reported in a non-peer-reviewed study that is available as a preprint, by Puray-246	
Chavez et al.24, who use ribosome profiling in SARS-CoV-2 infected cells to follow temporal 247	
changes at the viral and host RNA and translation level, allowing insights into how translational 248	
regulation impacts SARS-CoV-2 replication and host cell survival. Undoubtedly, many 249	
additional, complementary studies will appear in the near future. They will help us to understand 250	
the biology of SARS-CoV-2, which is directly relevant to medical progress that is needed to 251	
combat the current pandemic and to prepare for future pandemics. Finally, given the wealth of 252	
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high-quality fundamental research on a virus that was first described only some months ago, 253	
one of the most important take-home-messages may be that modern science can progress at 254	
an extraordinary pace, especially when the scientific community pulls together. 255	
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Figure legends 346	
Figure 1. Nsp1 interaction with the ribosome. 347	
a. Schematic of SARS-CoV-2 genome organization with the whole genome depicted at the top, 348	
Nsp1 coding sequence in the middle and a sequence alignment of Nsp1 C-terminal domain of 349	
SARS-CoV-2, SARS-CoV-1 and MERS-CoV in the lower part of the panel. The two alpha 350	
helices and the KH motif are marked by bars and an arrow, respectively. Colour coding of amino 351	
acids corresponds to default settings of the ClustalX alignment tool. 352	
b. Cartoon depicting the interaction between Nsp1 and the 40S ribosomal subunit, as revealed 353	
by the structural data. The C-terminal helices anchor Nsp1 in the mRNA entry channel, thereby 354	
blocking access for host transcripts (schematically represented in grey). The globular N-355	
terminus is not sufficiently resolved in the structures to be able to assign a clear position and 356	
function. 357	
Figure 2. Nsp1 impacts host gene expression by several mechanisms. 358	
Schematic representation of the main activities and mechanisms through which Nsp1 is thought 359	
to act in order to favour gene expression to viral transcripts, without shutting down mRNA 360	
translation completely.  361	
a. Nsp1 may have a role in shifting the balance between viral and cellular RNAs in its favour, 362	
by inducing the cleavage/decapping of host mRNAs, which leads to their degradation by cellular 363	
nucleases. 364	
b. The viral 5’ UTR (and in particular stem loop SL1) is likely a critical factor in directing 365	
ribosomes to the viral transcripts and overriding the translation block. Moreover, it has also been 366	
proposed that through Nsp1 autoregulation a total block of host mRNA translation may be 367	
prevented.  368	
